TRPV6 and neoplasm: These advances have led to preclinical and clinical studies assessing TRPV6 as a therapeutic target; the selective TRPV6 inhibitor SOR-C13 has shown promise in both in vivo models of cancer [193] and early clinical trials in patients with advanced tumours of epithelial origin [194].